alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

28,580 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 51–75 of 188 studies in Brain scans and imaging of type cohort or longitudinal study (page 3 of 8) · 28,580 in the whole library · How the 0–100 score works

Download bibliography of these 188 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Other subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 14,058 studies have no institution on record and are not counted here.

What “Brain scans and imaging” covers

Brain scans and imaging — MRI, PET and other scans: what they show, how early, and how reliably.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

The metabolic brain signature of cognitive resilience in the 80+: beyond Alzheimer pathologies

✓ Peer-reviewed alzhub usefulness score 64 out of 100. Brain : a journal of neurology 2019-04-01

Our main findings were: (i) FDG-PET uptake in the bilateral anterior cingulate cortex and anterior temporal pole was associated with baseline global cognition in cognitively stable 80+ (the resilience signature); (ii) established Alzheimer's disease imaging biomarkers did not predict baseline global cognition in this subset of participants; (iii) in the full MCSA 80+ and ADNI cohorts, amyloid burden and FDG-PET in the resilience signature were the stronger predictors of baseline global cognition; (iv) sex and systemic vascular health predicted FDG-PET in the resilience signature, suggesting vascular health maintenance as a potential pathway to preserve the metabolism of these areas; and (v) the resilience signature provided significant information about global longitudinal cognitive change even when considering amyloid status in both the MCSA and ADNI cohorts. 1 key finding →

Design: longitudinal study Participants: 192 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease

✓ Peer-reviewed alzhub usefulness score 64 out of 100. Annals of neurology 2016-07-25

CSF Aβ42 levels are tightly coupled with cortical amyloid load in the earliest stages of preclinical AD, and begin to decrease dramatically prior to the point when an abnormal threshold of cortical accumulation is detected with amyloid imaging. 1 key finding →

Design: longitudinal study Participants: 164 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Longitudinal β-Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non-Alzheimer Disease Pathophysiology

✓ Peer-reviewed alzhub usefulness score 64 out of 100. JAMA neurology 2016-10-01

Among the 174 participants (81 men [46.6%]; 93 women [53.4%]; mean [SD] age, 65.7 [8.9] years), a proportion (14%-17%) of individuals with neurodegeneration alone (SNAP) later demonstrated Aβ+. 1 key finding →

Design: cohort study Participants: 174 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Association of Regional White Matter Hyperintensities With Longitudinal Alzheimer-Like Pattern of Neurodegeneration in Older Adults

✓ Peer-reviewed alzhub usefulness score 64 out of 100. JAMA network open 2021-10-01

In 303 participants (mean [SD] age, 73.16 [5.19] years, 181 [60%] women, 96 [32%] non-Hispanic White, 113 [37%] Non-Hispanic Black, 94 [31%] Hispanic), baseline WMH volumes were associated with cortical thinning in medial temporal and frontal/parietal regions. 4 key findings →

Design: cohort study Participants: 303 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Symptomatology in 4-repeat tauopathies is associated with data-driven topology of [18F]-PI-2620 tau-PET signal

✓ Peer-reviewed alzhub usefulness score 64 out of 100. NeuroImage. Clinical 2023-04-11

As cerebral regions correlating with symptomatology differ depending on the clinical phenotype, a precise knowledge of clinical signs and symptoms is necessary when interpreting [18F]PI-2620 PET results. 1 key finding →

Design: longitudinal study Participants: 72 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Longitudinal Tau Positron Emission Tomography in Dementia with Lewy Bodies

✓ Peer-reviewed alzhub usefulness score 64 out of 100. Movement disorders : official journal of the Movement Disorder Society 2022-03-08

The annual increase of flortaucipir SUVr was greater in the middle and superior occipital, fusiform, and inferior parietal cortices in DLB (mean: 0.017, 0.019, 0.019, and 0.015, respectively) compared with the CU (mean: -0.006, -0.009, -0.003, and - 0.005, respectively; P < 0.05). 5 key findings →

Design: longitudinal study Participants: 22 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Tau accumulation in autosomal dominant Alzheimer's disease: a longitudinal [18F]flortaucipir study

✓ Peer-reviewed alzhub usefulness score 64 out of 100. Alzheimer's research & therapy 2023-05-25

Cortical tau accumulation is a key pathological event that partly defines Alzheimer's disease (AD) onset and is associated with cognitive decline and future disease progression. 5 key findings →

Design: cohort study Participants: 59 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Increased retention of tau PET ligand [18F]-AV1451 in Alzheimer's Disease Psychosis

✓ Peer-reviewed alzhub usefulness score 64 out of 100. Translational psychiatry 2022-02-26

Psychosis in Alzheimer's disease (AD) represents a distinct disease subtype with a more rapid progression of illness evidenced by an increased velocity of cognitive decline and a hastened mortality. 2 key findings →

Design: longitudinal study Participants: 17 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Tau and Amyloid Relationships with Resting-state Functional Connectivity in Atypical Alzheimer's Disease

✓ Peer-reviewed alzhub usefulness score 64 out of 100. Cerebral cortex (New York, N.Y. : 1991) 2021-02-05

The mechanisms through which tau and amyloid-beta (Aβ) accumulate in the brain of Alzheimer's disease patients may differ but both are related to neuronal networks. 1 key finding →

Design: longitudinal study Participants: 58 Evidence: moderate

Full summary, score breakdown and related studies → Original source

White matter hyperintensities, cognitive impairment and dementia: an update

✓ Peer-reviewed alzhub usefulness score 63 out of 100. Nature reviews. Neurology 2015-02-17

White matter hyperintensities (WMHs) in the brain are the consequence of cerebral small vessel disease, and can easily be detected on MRI. 2 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Trajectory of white matter hyperintensity burden preceding mild cognitive impairment

✓ Peer-reviewed alzhub usefulness score 63 out of 100. Neurology 2012-07-25

Acceleration in WMH burden, a common indicator of cerebrovascular disease in the elderly, is a pathologic change that emerges early in the presymptomatic phase leading to MCI. 2 key findings →

Design: longitudinal study Participants: 134 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer's Biomarkers in Daily Practice (ABIDE) Project

✓ Peer-reviewed alzhub usefulness score 63 out of 100. JAMA neurology 2017-12-01

Three- and 1-year progression risks were 86% (95% CI, 71%-95%) and 27% (95% CI, 17%-41%) when MRI results were abnormal, 82% (95% CI, 73%-89%) and 26% (95% CI, 20%-33%) when CSF test results were abnormal, and 89% (95% CI, 79%-95%) and 26% (95% CI, 18%-36%) when the results of both tests were abnormal. 4 key findings →

Design: longitudinal study Participants: 525 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Resting bold fMRI differentiates dementia with Lewy bodies vs Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 62 out of 100. Neurology 2011-04-27

Changes in functional connectivity in DLB indicate patterns of activation that are distinct from those seen in AD and may improve discrimination of DLB from AD and cognitively normal individuals. 3 key findings →

Design: longitudinal study Participants: 88 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Contribution of TDP and hippocampal sclerosis to hippocampal volume loss in older-old persons

✓ Peer-reviewed alzhub usefulness score 62 out of 100. Neurology 2019-11-22

Both AD and TDP/HS contribute to hippocampal volume loss in older-old persons, with TDP/HS more strongly associated with hippocampal volume than AD in Alzheimer dementia. 3 key findings →

Design: cohort study Participants: 232 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Longitudinal Association of Amyloid Beta and Anxious-Depressive Symptoms in Cognitively Normal Older Adults

✓ Peer-reviewed alzhub usefulness score 62 out of 100. The American journal of psychiatry 2018-01-12

Higher amyloid beta burden was associated with increasing anxious-depressive symptoms over time in cognitively normal older individuals. 4 key findings →

Design: longitudinal study Participants: 270 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Magnetic resonance imaging white matter hyperintensities and brain volume in the prediction of mild cognitive impairment and dementia

✓ Peer-reviewed alzhub usefulness score 61 out of 100. Archives of neurology 2008-01-01

High WMH was a predictor of progression from normal to MCI (adjusted hazard ratio [HR], 3.30; 95% confidence interval [CI], 1.33-8.17; P= .01) but not conversion from MCI to all-cause dementia. 2 key findings →

Design: cohort study Participants: 67 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

The AddNeuroMed framework for multi-centre MRI assessment of Alzheimer's disease: experience from the first 24 months

✓ Peer-reviewed alzhub usefulness score 61 out of 100. International journal of geriatric psychiatry 2011-01-01

A framework for multi-centre MRI studies of Alzheimer's disease has been established consisting of a harmonized MRI acquisition protocol across centres, rigorous QC at both the sites and central data analysis hub and an automated image analysis pipeline. 4 key findings →

Design: longitudinal study Participants: 378 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 28,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,580 records, built mostly from automated pulls of Europe PMC (62.2% of the library) and OpenAlex (17.8%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.6% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed